Data di Pubblicazione:
2020
Abstract:
Primary or secondary nonresponse to anti-TNF-alpha due to immunogenicity or treatment-related side effects and the growing presence of innovative biological therapies targeting different cytokines and immune processes raise a clear need for predictors of efficacy for anti-TNF-alpha treatment.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Crohn’s disease; MMP; anti-TNF-α; biologics; inflammatory bowel disease; innate cytokines; long-term efficacy; predictors; short-term efficacy; ulcerative colitis
Elenco autori:
Lopetuso, L. R.; Gasbarrini, A.
Link alla scheda completa:
Pubblicato in: